The story of copyright's flagship drug presents a complex case for stakeholders in the drug sector. While initially a blockbuster success, generating billions, the patent lapse and the subsequent flood of cheaper https://pharma636126.qodsblog.com/41922666/sildenafil-and-pharma-a-risky-bet